Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Seikagaku Eyes FDA Re-Filing of Herniated Disk Drug within 1 Year
Seikagaku aims for the US re-submission of SI-6603 (condoliase), its Ferring-partnered investigational treatment for lumbar disc herniation, “within one year,” President and CEO Ken Mizutani said on May 16. SI-6603 is sold in Japan by Kaken Pharmaceutical under the trade…
To read the full story
Related Article
- Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
- FDA Rejects Seikagaku’s Herniated Disk Drug
March 14, 2025
BUSINESS
- Tanabe Unveils PIII Data for EPP/XLP Therapy, Backing Filing Plans
March 31, 2026
- Meiji Pharma Invests in Centivax to Support Vaccine R&D
March 31, 2026
- Takeda’s Zasocitinib Logs Positive Results in Global PIII Psoriasis Trials
March 31, 2026
- Ferring, Nippon Kayaku to Co-Promote Bladder Cancer Gene Therapy
March 31, 2026
- Mochida to Acquire Urece from Fuji Yakuhin for 13.5 Billion Yen
March 31, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…